{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:35:25Z","timestamp":1791326125689,"version":"4.3.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.pharma.2024.05.001","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T16:03:41Z","timestamp":1715184221000},"page":"873-885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comprehensive medication management (CMM): Application of a new pharmaceutical practice in onco-hematology"],"prefix":"10.1016","volume":"82","author":[{"given":"Sabah","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Zohra Nadjet","family":"Mekaouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halima","family":"Rouabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souad","family":"Brahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Boudia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Yafour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Bereksi Reguig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houari","family":"Toumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pharma.2024.05.001_bib0215","first-page":"1573","article-title":"New anticancer agents: role of clinical pharmacy services","volume":"34","author":"Leveque","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharma.2024.05.001_bib0220","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s11096-020-00992-8","article-title":"Significance of a clinical pharmacist-led comprehensive medication management program for hospitalized oncology patients","volume":"42","author":"Umar","year":"2020","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.pharma.2024.05.001_bib0225","series-title":"The patient-centered medical home: integrating comprehensive medication management to optimize patient outcomes","year":"2012"},{"key":"10.1016\/j.pharma.2024.05.001_bib0230","unstructured":"The patient care process for delivering comprehensive medication management (CMM): optimizing medication use in patient-centered, team-based care settings. CMM in primary care research team 2018. [Available at http:\/\/www.accp.com\/cmm_care_process]."},{"issue":"9","key":"10.1016\/j.pharma.2024.05.001_bib0235","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/jac5.1496","article-title":"Establishing a common language for the comprehensive medication management patient care process: applying implementation science to standardize care delivery","volume":"4","author":"Blanchard","year":"2021","journal-title":"J Am Coll Clin Pharm"},{"key":"10.1016\/j.pharma.2024.05.001_bib0240","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/jac5.1181","article-title":"The practice management components needed to support comprehensive medication management in primary care clinics","volume":"3","author":"Pestka","year":"2020","journal-title":"J Am Coll Clin Pharm"},{"issue":"4","key":"10.1016\/j.pharma.2024.05.001_bib0245","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jgo.2017.04.005","article-title":"Implementing a pharmacist-led, individualized medication assessment and planning (iMAP) intervention to reduce medication related problems among older adults with cancer","volume":"8","author":"Nightingale","year":"2017","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.pharma.2024.05.001_bib0250","first-page":"457","article-title":"Impact of clinical pharmacy services in a hematology\/oncology inpatient setting","volume":"35","author":"Delpeuch","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharma.2024.05.001_bib0255","series-title":"Pharmacotherapy casebook: a patient-focused approach","article-title":"Documentation of patient encounters and interventions","author":"Armistead","year":"2021"},{"issue":"5","key":"10.1016\/j.pharma.2024.05.001_bib0260","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","article-title":"Predictive validity of a medication adherence measure in an outpatient setting","volume":"10","author":"Morisky","year":"2008","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.pharma.2024.05.001_bib0265","series-title":"PCNE classification for drug-related problems V9.1","year":"2020"},{"key":"10.1016\/j.pharma.2024.05.001_bib0270","unstructured":"Drugs.com [Internet]. Interactions checker from Drugs.com. C2000-2022. [Updated: April 2023, cited: 25 April 2023. Available from: https:\/\/www.drugs.com\/drug_interactions.html]."},{"key":"10.1016\/j.pharma.2024.05.001_bib0275","unstructured":"Vidal.fr [Internet]. Les interactions m\u00e9dicamenteuses. C2022. [Updated: July 2021, cited: 25 April 2023. Available from: https:\/\/www.vidal.fr\/medicaments\/utilisation\/prendre-traitement\/interactions-medicamenteuses.html]."},{"key":"10.1016\/j.pharma.2024.05.001_bib0280","unstructured":"Theriaque.org [Internet]. Analyse. [Updated: February 2023, cited: 25 April 2023. Available from: https:\/\/www.theriaque.org\/apps\/interaction\/itr_ordonnance.php]."},{"key":"10.1016\/j.pharma.2024.05.001_bib0285","series-title":"Stockley's drugs interactions","year":"2010"},{"key":"10.1016\/j.pharma.2024.05.001_bib0290","series-title":"Thesaurus des interactions m\u00e9dicamenteuses [internet]","year":"2020"},{"issue":"3","key":"10.1016\/j.pharma.2024.05.001_bib0295","first-page":"252","article-title":"Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction","volume":"22","author":"Hatoum","year":"1988","journal-title":"Drug Intell Clin Pharm"},{"key":"10.1016\/j.pharma.2024.05.001_bib0300","unstructured":"M\u00e9dicaments.gouv.fr [Internet]. RCP Perindopril. [Updated: April 2023, cited: 25 April 2023. Available from: https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=61113361&typedoc=R]."},{"key":"10.1016\/j.pharma.2024.05.001_bib0305","series-title":"M\u00e9dicaments n\u00e9cessitant une adaptation a la fonction r\u00e9nale selon liste Epernay","year":"2016"},{"key":"10.1016\/j.pharma.2024.05.001_bib0310","unstructured":"ANSM.sante.fr [Internet]. RCP lenalidomide. [Updated: May 2020, Cited: 25 April 2023. Available from: http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0353318.htm]."},{"key":"10.1016\/j.pharma.2024.05.001_bib0315","unstructured":"ANSM.sante.fr [Internet]. RCP bactrim. [Updated: June 2017, cited: 25 April 2023. Available from: http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0298166.htm]."},{"key":"10.1016\/j.pharma.2024.05.001_bib0320","unstructured":"M\u00e9dicaments.gouv.fr [En ligne]. RCP bleomycine. [Updated: April 2023, cited: 25 April 2023. Available from: https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=62789360&typedoc=R#RcpPosoAdmin]."},{"key":"10.1016\/j.pharma.2024.05.001_bib0325","series-title":"Antiemetics: ASCO guideline update","year":"2020"},{"key":"10.1016\/j.pharma.2024.05.001_bib0330","unstructured":"Eviq.org [Internet]. Lymphoma bendamustine and rituximab. [Updated: Octobre 2021, cited: 25 April 2023. Available from: https:\/\/www.eviq.org.au\/haematology-and-bmt\/lymphoma\/3794-lymphoma-bendamustine-and-rituximab]."},{"issue":"3","key":"10.1016\/j.pharma.2024.05.001_bib0335","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ygyno.2009.10.070","article-title":"The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment","volume":"116","author":"O\u2019Cearbhaill","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pharma.2024.05.001_bib0340","unstructured":"M\u00e9dicaments.gouv.fr [Internet]. RCP oxaliplatine. [Updated: April 2023, cited: 25 April 2023. Available from: https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=67127720&typedoc=R#RcpIncompatibilites]."},{"key":"10.1016\/j.pharma.2024.05.001_bib0345","unstructured":"M\u00e9dicaments.gouv.fr [Internet]. RCP gemcitabine. [Updated: April 2023, cited: 25 April 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/gemzar-article-30-referral-annex-i-ii-iii_fr.pdf]."},{"key":"10.1016\/j.pharma.2024.05.001_bib0350","unstructured":"M\u00e9dicaments.gouv.fr [Internet]. RCP acide zol\u00e9dronique. [Updated: Avril 2023, cited: 25 April 2023. Available from: https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=66716961]."},{"key":"10.1016\/j.pharma.2024.05.001_bib0355","series-title":"P\u00e9metrexed","year":"2021"},{"key":"10.1016\/j.pharma.2024.05.001_bib0360","series-title":"Recommandations pour l\u2019utilisation des alternatives de la ranitidine\u00a0\u2013\u00a0point d\u2019information","year":"2019"},{"key":"10.1016\/j.pharma.2024.05.001_bib0365","unstructured":"M\u00e9dicaments.gouv.fr [Internet]. RCP fosapr\u00e9pitant. [Updated: February 2018, cited: 25 April 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ivemend-epar-product-information_fr.pdf]."},{"key":"10.1016\/j.pharma.2024.05.001_bib0370","series-title":"Doses cumul\u00e9es maximales des anticanc\u00e9reux","year":"2021"},{"key":"10.1016\/j.pharma.2024.05.001_bib0375","series-title":"Fiche XELODA\u00ae professionnels de sant\u00e9","year":"2018"},{"key":"10.1016\/j.pharma.2024.05.001_bib0380","unstructured":"Eviq.org [Internet]. Management of treatment-induced diarrhoea. [Updated: November 2020, cited: 25 April 2023. Available from: https:\/\/www.eviq.org.au\/clinical-resources\/side-effect-and-toxicity-management\/gastrointestinal\/779-treatment-induced-diarrhoea#management]."},{"key":"10.1016\/j.pharma.2024.05.001_bib0385","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.critrevonc.2015.08.025","article-title":"To adhere or not to adhere: rates and reasons of medication adherence in hematological cancer patients","volume":"97","author":"Hall","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.pharma.2024.05.001_bib0390","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1186\/s12885-017-3735-1","article-title":"Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation","volume":"17","author":"Bouwman","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharma.2024.05.001_bib0395","doi-asserted-by":"crossref","DOI":"10.1111\/ecc.12767","article-title":"Prescribing errors intercepted by pharmacist intervention in care of patients hospitalised with breast and gynaecological cancer at a Brazilian teaching hospital","volume":"27","author":"Ferracini","year":"2018","journal-title":"Eur J Cancer Care"},{"issue":"1","key":"10.1016\/j.pharma.2024.05.001_bib0400","first-page":"22","article-title":"Evaluation of eligibility criteria used to identify patients for medication therapy management services: a retrospective cohort study in a medicare advantage part D population","volume":"22","author":"Lee","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"15","key":"10.1016\/j.pharma.2024.05.001_bib0405","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.3390\/jcm11154558","article-title":"New oral antitumor drugs and medication safety in uro-oncology: implications for clinical practice based on a subgroup analysis of the AMBORA trial","volume":"11","author":"Schlichtig","year":"2022","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.pharma.2024.05.001_bib0410","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00520-012-1661-y","article-title":"The impact of medication therapy management in older oncology patients","volume":"21","author":"Yeoh","year":"2013","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.pharma.2024.05.001_bib0415","doi-asserted-by":"crossref","DOI":"10.1590\/s2175-97902018000200221","article-title":"Impact of a medication therapy management service offered to patients in treatment of breast cancer","volume":"54","author":"Amaral","year":"2018","journal-title":"Braz J Pharm Sci"},{"issue":"2","key":"10.1016\/j.pharma.2024.05.001_bib0420","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11096-010-9367-z","article-title":"Clinical pharmacists\u2019 interventions in a German university hospital","volume":"32","author":"Langebrake","year":"2010","journal-title":"Pharm World Sci"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924000683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924000683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T20:34:01Z","timestamp":1724963641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450924000683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0003450924000683"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2024.05.001","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive medication management (CMM): Application of a new pharmaceutical practice in onco-hematology","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2024.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}